LAUSR

Patients with primary membranous nephropaty experience a spontaneous remission rate between 30-40%. AntiPLA2R antibodies are involved in the pathogenesis of the disease. Some studies demonstrated that levels of circulating anti-PLA2R in the beginning of the disease revealed a strong correlation with clinical disease activity, and it could help discriminate against those who will make spontaneous remission The principal objetive was to analize the spontaneous remission rate in patients with membranous nephropaty with positive antiPLA2R antiboidies and study clinical and serological variables associated. A retrospective analysis studied the assocaition between analitis, clinical and serological variables of patients with with spontaneous remission and membranous nephropaty who were diagnosed in between 2015 and 2018 in Ramon y Cajal Hospital. We included 13 patients with primary positive antiPLA2R antibodies membranous nephropaty. Patients ha a mean age of 61,6 ± 20 and a 64.3% were males. All of them had nephrotic syndrome in the onset disease. Patients were aged 6,6 ± 3.8 gr/24horas, in serum albumine 2.3 ± 0.5 g/L and the serum Creatinine (Cr) was 1 ± 0.5 mg/dl. Medium AntiPLA2R tittle was ±. All the patients were treated at the diagnosis time with ARB/ACE inhibitors . 7 of the 13 (53.8%) patients experienced a spontaneous remission of the nephrotic syndrome. The mean time to spontaneous remission was 4.8 ± 2.4 months. Patients who presented spontaneous remission debuted with lower serum Cr at debut. No significative differences were found in between remisión rate in association with total proteinuria neither PLA2R titles in the beginning. In our experience, approximately a 50% of patients with membranous nephropaty experienced an spontaneous remission. There was no significative association in between AntiPLA2R titles and spontaneous remission rate in our study. Patients with better renal function in the diagnosis were more frequently associated with spontaneous remission.